日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer

口服首创小分子 RSK 抑制剂可抑制前列腺癌中的 AR 变异和肿瘤生长

Miho Ushijima, Masaki Shiota, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

癌症基因组分析发现膀胱癌二氢嘧啶脱氢酶缺乏可增强对吉西他滨的敏感性

Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, 

Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer

晚期前列腺癌中 HSD3B1 多态性对转移体积和体细胞 HSD3B1 改变的临床影响

Masaki Shiota, Naohiro Fujimoto, Yohei Sekino, Shigehiro Tsukahara, Shohei Nagakawa, Dai Takamatsu, Tatsuro Abe, Fumio Kinoshita, Shohei Ueda, Miho Ushijima, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Takeshi Uchiumi, Yoshinao Oda, Masatoshi Eto

Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression

去势抵抗性前列腺癌中 YB-1 基因扩增与雄激素受体异常表达的关系

Masaki Shiota, Yohei Sekino, Shigehiro Tsukahara, Tatsuro Abe, Fumio Kinoshita, Kenjiro Imada, Shohei Ueda, Miho Ushijima, Shohei Nagakawa, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Takeshi Uchiumi, Yoshinao Oda, Masatoshi Eto

High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer

高通量筛选确定 5-HT 受体是 AR 的调节剂和前列腺癌的治疗靶点

Momoe Itsumi, Masaki Shiota, Yohei Sekino, Miho Ushijima, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Shunichi Kajioka, Takeshi Uchiumi, Masatoshi Eto

Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy

吸烟会增强雄激素受体活性并增加对抗雄激素治疗的抵抗力

Masaki Shiota, Miho Ushijima, Kenjiro Imada, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Katsunori Tatsugami, Shunichi Kajioka, Masatoshi Eto

Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants

恩杂鲁胺耐药前列腺癌通过异常雄激素受体及其变体对紫杉烷产生附带耐药性

Masaki Shiota, Takashi Dejima, Yoshiaki Yamamoto, Ario Takeuchi, Kenjiro Imada, Eiji Kashiwagi, Junichi Inokuchi, Katsunori Tatsugami, Shunichi Kajioka, Takeshi Uchiumi, Masatoshi Eto

Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2

雌马酚通过 S 期激酶相关蛋白 2 降解雄激素受体来抑制前列腺癌的生长

Momoe Itsumi, Masaki Shiota, Ario Takeuchi, Eiji Kashiwagi, Junichi Inokuchi, Katsunori Tatsugami, Shunichi Kajioka, Takeshi Uchiumi, Seiji Naito, Masatoshi Eto, Akira Yokomizo

Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer

抑制蛋白激酶 C/Twist1 信号可增强前列腺癌中雄激素剥夺和恩杂鲁胺的抗癌作用

Masaki Shiota, Akira Yokomizo, Ario Takeuchi, Kenjiro Imada, Eiji Kashiwagi, YooHyun Song, Junichi Inokuchi, Katsunori Tatsugami, Takeshi Uchiumi, Seiji Naito

PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells

PMA 诱导前列腺癌细胞雄激素受体下调和细胞凋亡

Momoe Itsumi, Masaki Shiota, Akira Yokomizo, Ario Takeuchi, Eiji Kashiwagi, Takashi Dejima, Junichi Inokuchi, Katsunori Tatsugami, Takeshi Uchiumi, Seiji Naito